First National Bank of Omaha Buys Shares of 9,299 Lantheus Holdings, Inc. $LNTH

First National Bank of Omaha purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the third quarter, Holdings Channel.com reports. The firm purchased 9,299 shares of the medical equipment provider’s stock, valued at approximately $477,000.

Other large investors have also made changes to their positions in the company. Hantz Financial Services Inc. raised its position in Lantheus by 412.5% during the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 396 shares in the last quarter. Elevation Point Wealth Partners LLC acquired a new stake in shares of Lantheus in the 2nd quarter valued at $26,000. First Horizon Corp bought a new stake in Lantheus in the third quarter worth $26,000. Osterweis Capital Management Inc. acquired a new position in Lantheus during the second quarter worth $36,000. Finally, Pilgrim Partners Asia Pte Ltd bought a new position in Lantheus during the third quarter valued at about $59,000. Institutional investors own 99.06% of the company’s stock.

More Lantheus News

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: TD Cowen reaffirmed coverage and updated its financial model around upcoming Q4 results; the firm cut its price target to $75 but keeps a Buy rating, providing analyst support for the stock. TD Cowen Updates Financial Model
• Positive Sentiment: Brokerage consensus remains favorable — Lantheus has a “Moderate Buy” consensus from analysts, which can underpin demand into earnings. Consensus Rating: Moderate Buy
• Positive Sentiment: Technical/relative-strength screens show improving momentum for LNTH, which can attract momentum and quant flows. Stocks with Rising Relative Strength
• Neutral Sentiment: Lantheus is set to report quarterly results this week; earnings and guidance will likely be the primary near-term catalyst and could drive volatility. Earnings Release Notice
• Neutral Sentiment: Analyst modeling updates and commentary (multiple outlets) discuss valuation after a short-term rebound — useful for investors evaluating entry points but not an immediate catalyst. TD Cowen Model Update (InsiderMonkey)
• Neutral Sentiment: Reported February short-interest data is anomalous/zero in the feed (no meaningful short-interest signal to drive moves). (Internal data)
• Negative Sentiment: Press coverage highlights disclosure probes into Lantheus, raising questions about management credibility and the reliability of Pylarify forecasts — this is a reputational and regulatory risk that could pressure the stock if investigations produce adverse findings. Disclosure Probes Coverage

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Truist Financial raised their price objective on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Finally, Mizuho lifted their target price on shares of Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Five equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and a consensus target price of $78.00.

Lantheus Stock Up 0.2%

LNTH stock opened at $73.18 on Friday. The business’s 50-day simple moving average is $67.10 and its 200 day simple moving average is $59.57. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51. The company has a market cap of $4.85 billion, a PE ratio of 30.75 and a beta of -0.08. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $111.29.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.